Founded in 2008, AVM Biotechnology has its headquarters in Seattle. AVM Biotechnology is dedicated to the discovery, development, and commercialization of cell therapy-enabling technologies for immuno-oncology and auto-immunity. AVM Biotechnology’s lead technology ‘AVM0703’ is ready for Phase 2/3 clinical trials in combination with cell-based therapies. AVM0703 has a lymphodepletion profile comparable to chemotherapy, including a direct therapeutic killing activity and is being positioned to replace Fludarabine, Cyclophosphamide, Busulfan and similar lymphodepleting agents.